home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

446.78 +2.86 (+0.64%)

Official Closing Price Updated: 4:15 PM EDT, Apr 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

72 73 Next >

Will the Biotech sector sustain its momentum in 2024?

January 04, 2024

The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.

Via MarketBeat

Topics ETFs

The Best Stocks to Invest $1,000 in Right Now ↗

January 04, 2024

It's not too late to get in on these market beaters.

Via The Motley Fool

Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics ↗

January 04, 2024

CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead.

Via The Motley Fool

3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition ↗

January 03, 2024

Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside.

Via InvestorPlace

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Climbs to New 52-Week High

January 03, 2024

Via Investor Brand Network

January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway. ↗

January 03, 2024

These stocks are smart picks to buy now, regardless of whether the S&P 500 stocks start off 2024 poorly.

Via The Motley Fool

Topics Stocks

Decoding Vertex Pharmaceuticals's Options Activity: What's the Big Picture? ↗

December 27, 2023

Via Benzinga

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow ↗

December 27, 2023

With a new medicine on the market and plenty of money, Vertex is in great shape.

Via The Motley Fool

3 Biotech Stocks Set for Breakthroughs in 2024 ↗

January 02, 2024

With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks.

Via InvestorPlace

2 gene-editing stocks reshaping hereditary disease treatments

January 02, 2024

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal

Via MarketBeat

Prediction: These 3 Stocks Will Soar in 2024 ↗

January 01, 2024

Investors could enjoy an especially happy new year with these great stocks.

Via The Motley Fool

1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024 ↗

December 31, 2023

Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name.

Via The Motley Fool

Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade. ↗

December 30, 2023

These stocks offer attractive risk-reward profiles.

Via The Motley Fool

Market Whales and Their Recent Bets on VRTX Options ↗

December 22, 2023

Via Benzinga

How Is The Market Feeling About Vertex Pharmaceuticals? ↗

December 21, 2023

Via Benzinga

$1000 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

December 19, 2023

Via Benzinga

2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now ↗

December 29, 2023

It's been a crazy year across sectors, but winners remain.

Via The Motley Fool

CRISPR Therapeutics sets sights on gene-editing cures for disease

December 27, 2023

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for

Via MarketBeat

3 Monster Stocks to Buy Without Any Hesitation ↗

December 27, 2023

These are easy choices for investors seeking market-beating long-term gains.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 25, 2023

Via Benzinga

3 Top Stocks to Buy Hand Over Fist Before the End of 2023 ↗

December 25, 2023

These are ideal stocks to buy sooner rather than later.

Via The Motley Fool

Editas Just Caught a Break Thanks to Vertex Pharmaceuticals ↗

December 23, 2023

Editas isn't out of the woods yet, but it's better off than before.

Via The Motley Fool

1 Green Flag and 1 Red Flag for Bluebird Bio Stock ↗

December 23, 2023

The stock has been in the news lately.

Via The Motley Fool

5 Top Stocks to Buy With Your End-of-the-Year Bonus ↗

December 23, 2023

Your bonus could become the gift that keeps on giving.

Via The Motley Fool

Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock? ↗

December 22, 2023

Both develop medicines for rare diseases, and each aims to conquer a niche market.

Via The Motley Fool

Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock? ↗

December 22, 2023

The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction.

Via The Motley Fool

3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’ ↗

December 21, 2023

It's now time to take a look at these three biotech stocks to buy, as each one is currently within TradeSmith's "Green Zone."

Via InvestorPlace

Should you consider NASDAQ:VRTX for quality investing? ↗

December 21, 2023

Reasonable Growth, Debt Levels, and a High ROIC Make VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) Appealing to Quality Investors.

Via Chartmill

Is Vertex Pharmaceuticals Sitting on a Gold Mine? ↗

December 21, 2023

Vertex shares have climbed about 40% this year.

Via The Motley Fool

CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief ↗

December 20, 2023

The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy.

Via InvestorPlace

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com